ANNEXON INC. DL-,001

Annexon presented at the Cantor Fitzgerald conference data showing Vonaprument significantly improved vision preservation in geographic atrophy in a phase II study and protects photoreceptors. The phase III ARCHER II trial completed recruitment with 659 patients six weeks ahead of schedule, has over 90% treatment adherence and a dropout rate below 10%. Ellipsoid zone markers appear to support efficacy, and Annexon views Vonaprument as a potential replacement for first complement inhibitors. In Guillain‑Barré syndrome, open‑label data showed a very rapid response rate; the company has already filed for approval in Europe and plans further regulatory activities. » Mere på de.investing.com

Annexon has added a second primary endpoint at 24 months to the ongoing phase‑3 ARCHER II trial of Vonaprument in dry age‑related macular degeneration; efficacy will now be assessed independently at 15 and 24 months. The double‑blind study has enrolled 659 participants (recruitment completed July 2025), with a dropout rate under 10% and compliance above 95%. An independent data monitoring committee will assess the 15‑month endpoint, with results expected in Q4 2026; study completion including 24‑month analyses is planned for Q3 2027. After month 24, patients may enter an open‑label extension with monthly Vonaprument treatment; primary endpoints measure confirmed losses of 15 letters in best‑corrected visual acuity, and safety and retinal secondary endpoints are also planned. » Mere på de.investing.com

Annexon has appointed Dr. med. Mark S. Blumenkranz to its board of directors; at the same time Muneer Satter is leaving the board after more than 11 years. Blumenkranz is emeritus professor of ophthalmology at Stanford University, a co‑founder of several ophthalmology and life‑sciences companies, and brings broad experience in clinical and entrepreneurial development. Annexon is developing Vonaprument for the treatment of geographic atrophy and runs programs against neuroinflammatory diseases with a focus on the molecule C1q. » Mere på de.investing.com